Hedwig Sutterlüty

2.1k total citations · 1 hit paper
30 papers, 1.5k citations indexed

About

Hedwig Sutterlüty is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Hedwig Sutterlüty has authored 30 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 7 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Hedwig Sutterlüty's work include Fibroblast Growth Factor Research (13 papers), Epigenetics and DNA Methylation (9 papers) and Kruppel-like factors research (6 papers). Hedwig Sutterlüty is often cited by papers focused on Fibroblast Growth Factor Research (13 papers), Epigenetics and DNA Methylation (9 papers) and Kruppel-like factors research (6 papers). Hedwig Sutterlüty collaborates with scholars based in Austria, United States and Switzerland. Hedwig Sutterlüty's co-authors include C Wirbelauer, Uli Müller, Eric Chatelain, Walter Berger, M. Micksche, Leonilla Elbling, Barbara Haigl, Petra Heffeter, Heidi A. Lane and Richard M. Neve and has published in prestigious journals such as PLoS ONE, Nature Cell Biology and Cancer Research.

In The Last Decade

Hedwig Sutterlüty

29 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells

1999 610 citations Hedwig Sutterlüty, Eric Chatelain et al. Nature Cell Biology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hedwig Sutterlüty Austria	15	1.1k	781	240	163	107	30	1.5k
Viswanathan Muthusamy United States	17	996 0.9×	483 0.6×	208 0.9×	154 0.9×	64 0.6×	28	1.4k
Jianhai Jiang China	23	955 0.9×	501 0.6×	274 1.1×	176 1.1×	123 1.1×	63	1.5k
Manuela Porru Italy	27	1.4k 1.3×	693 0.9×	303 1.3×	69 0.4×	141 1.3×	48	2.1k
Jeremy P. Blaydes United Kingdom	32	1.6k 1.5×	987 1.3×	342 1.4×	133 0.8×	119 1.1×	54	2.2k
Jiro Kikuchi Japan	27	1.5k 1.4×	594 0.8×	209 0.9×	138 0.8×	72 0.7×	89	2.2k
Venkatesh Krishnan United States	20	1.1k 1.0×	758 1.0×	285 1.2×	153 0.9×	242 2.3×	35	2.3k
Caining Jin United States	22	922 0.9×	512 0.7×	287 1.2×	96 0.6×	157 1.5×	28	1.3k
Jürgen Sonnemann Germany	25	1.0k 1.0×	446 0.6×	190 0.8×	134 0.8×	234 2.2×	62	1.6k
Limo Chen United States	18	816 0.8×	1.0k 1.3×	257 1.1×	121 0.7×	276 2.6×	26	1.9k
Jian H. Song United States	20	977 0.9×	387 0.5×	356 1.5×	182 1.1×	221 2.1×	46	1.4k

Countries citing papers authored by Hedwig Sutterlüty

Since Specialization

Citations

This map shows the geographic impact of Hedwig Sutterlüty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hedwig Sutterlüty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hedwig Sutterlüty more than expected).

Fields of papers citing papers by Hedwig Sutterlüty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hedwig Sutterlüty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hedwig Sutterlüty. The network helps show where Hedwig Sutterlüty may publish in the future.

Co-authorship network of co-authors of Hedwig Sutterlüty

This figure shows the co-authorship network connecting the top 25 collaborators of Hedwig Sutterlüty. A scholar is included among the top collaborators of Hedwig Sutterlüty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hedwig Sutterlüty. Hedwig Sutterlüty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sutterlüty, Hedwig, et al.. (2023). Quantifying telomere transcripts as tool to improve risk assessment for genetic instability and genotoxicity. Mutation Research/Genetic Toxicology and Environmental Mutagenesis. 891. 503690–503690. 2 indexed citations

König, Theresa, Raphael Wurm, Christoph Hotzy, et al.. (2022). C9orf72 repeat length might influence clinical sub-phenotypes in dementia patients. Neurobiology of Disease. 175. 105927–105927. 6 indexed citations

Wagner, Gabriel, Anna Fenzl, Elisa Einwallner, et al.. (2021). LMO3 reprograms visceral adipocyte metabolism during obesity. Journal of Molecular Medicine. 99(8). 1151–1171. 13 indexed citations

Sutterlüty, Hedwig, et al.. (2019). Spatial signal repression as an additional role of Sprouty2 protein variants. Cellular Signalling. 62. 109332–109332.

Siegwart, Gerald, et al.. (2019). Sprouty3 and Sprouty4, Two Members of a Family Known to Inhibit FGF-Mediated Signaling, Exert Opposing Roles on Proliferation and Migration of Glioblastoma-Derived Cells. Cells. 8(8). 808–808. 17 indexed citations

Haigl, Barbara, et al.. (2016). MicroRNA-21 Increases Proliferation and Cisplatin Sensitivity of Osteosarcoma-Derived Cells. PLoS ONE. 11(8). e0161023–e0161023. 49 indexed citations

Haigl, Barbara, et al.. (2015). The increased Sprouty4 expression in response to serum is transcriptionally controlled by Specific protein 1. The International Journal of Biochemistry & Cell Biology. 64. 220–228. 10 indexed citations

Sutterlüty, Hedwig, et al.. (2014). Sprouty4 interferes with cell proliferation and migration of breast cancer-derived cell lines. Tumor Biology. 35(5). 4447–4456. 26 indexed citations

Haigl, Barbara, et al.. (2014). Expression of microRNA-21 in non-small cell lung cancer tissue increases with disease progression and is likely caused by growth conditional changes during malignant transformation. International Journal of Oncology. 44(4). 1325–1334. 10 indexed citations

10.

Hofer, Philipp, Andreas Baierl, Stephan Madersbacher, et al.. (2013). MNS16A tandem repeat minisatellite of human telomerase gene and prostate cancer susceptibility. Mutagenesis. 28(3). 301–306. 9 indexed citations

11.

Haigl, Barbara, et al.. (2013). Sprouty2 but not Sprouty4 is a potent inhibitor of cell proliferation and migration of osteosarcoma cells. FEBS Letters. 587(16). 2597–2605. 22 indexed citations

12.

Heinzle, Christine, Hedwig Sutterlüty, Michael Grusch, et al.. (2011). Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy. Expert Opinion on Therapeutic Targets. 15(7). 829–846. 40 indexed citations

13.

Haigl, Barbara, et al.. (2010). Sprouty4 levels are increased under hypoxic conditions by enhanced mRNA stability and transcription. Biological Chemistry. 391(7). 813–21. 22 indexed citations

14.

Haigl, Barbara, et al.. (2010). Bimodal expression of Sprouty2 during the cell cycle is mediated by phase-specific Ras/MAPK and c-Cbl activities. Cellular and Molecular Life Sciences. 67(19). 3299–3311. 17 indexed citations

15.

Gauglhofer, Christine, Chantal Rodgarkia‐Dara, Michael Grusch, et al.. (2008). NORE1B Is a Putative Tumor Suppressor in Hepatocarcinogenesis and May Act via RASSF1A. Cancer Research. 69(1). 235–242. 21 indexed citations

16.

Heffeter, Petra, Michael A. Jakupec, Wilfried Körner, et al.. (2007). Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24). Biochemical Pharmacology. 73(12). 1873–1886. 85 indexed citations

17.

Kubista, Bernd, Klemens Trieb, Florian Sevelda, et al.. (2006). Anticancer effects of zoledronic acid against human osteosarcoma cells. Journal of Orthopaedic Research®. 24(6). 1145–1152. 74 indexed citations

18.

Heffeter, Petra, Michael A. Jakupec, Wilfried Körner, et al.. (2005). Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24). Biochemical Pharmacology. 71(4). 426–440. 124 indexed citations

19.

Neve, Richard M., Hedwig Sutterlüty, Nick Pullen, et al.. (2000). Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene. 19(13). 1647–1656. 127 indexed citations

20.

Sutterlüty, Hedwig, et al.. (1999). p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nature Cell Biology. 1(4). 207–214. 610 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact